XPGgene rs751402 C>T polymorphism and cancer risk: Evidence from 22 publications

// Haixia Zhou 1, * , Ting-Yan Shi 2, * , Wenwen Zhang 3, * , Qiwen Li 3 , Jinhong Zhu 4 , Jing He 1, 5 and Jichen Ruan 1 1 Department of Hematology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325027, Zhejiang, China 2 Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai 200032, China 3 State Key Laboratory of Oncology in South China, Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, Guangdong, China 4 Molecular Epidemiology Laboratory and Department of Laboratory Medicine, Harbin Medical University Cancer Hospital, Harbin 150040, Heilongjiang, China 5 Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou 510623, Guangdong, China * These authors have contributed equally to this work Correspondence to: Jichen Ruan, email: ruanjichen@163.com Jing He, email: hejing198374@gmail.com Keywords: DNA repair, XPG, polymorphism, cancer susceptibility, meta-analysis Received: May 12, 2017 Accepted: June 12, 2017 Published: July 18, 2017 ABSTRACT The Xeroderma pigmentosum group G ( XPG ) gene promotes recognition and excision of damaged DNA during the DNA repair process. We conducted a comprehensive search of the MEDLINE, EMBASE, and Chinese Biomedical databases for publications evaluating the association XPG gene rs751402 C>T polymorphism and overall cancer risk. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were adopted to assess the strength of the association. A total of 22 publications encompassing 10538 cases and 10511 control subjects were included in the final meta-analysis. We found the polymorphism to be associated with increased cancer risk (TT vs. CC: OR = 1.18, 95% CI = 1.01–1.38, P = 0.040; CT vs. CC: OR = 1.12, 95% CI = 1.01–1.24, P = 0.040; and CT/TT vs. CC: OR = 1.12, 95% CI = 1.002–1.26, P = 0.045). Stratification by cancer type indicated that this polymorphism may increase the risk of gastric cancer and hepatocellular carcinoma, which was further confirmed by a false-positive report probability analysis. Genotype-based mRNA expression provides further evidence that this polymorphism is associated with altered XPG mRNA expression. This meta-analysis suggests XPG gene rs751402 C>T polymorphism correlates with overall cancer risk, especially for gastric cancer and hepatocellular carcinoma.